Companies

Cambridge Cognition

Overview

Cambridge Cognition develops cognition tests, known as CANTAB, that can be used to diagnose early-stage neurological diseases. The rights to the tests were acquired from former Aim company CeNeS Pharmaceuticals. Cambridge Cognition raised £5m at 70p a share prior to floating on 18 April 2013 at a valuation of £11.8m.

Sector: Health

News blog

• Cambridge Cognition Posted: 28/02/2020
• Cambridge Cognition Posted: 19/03/2019
• Cambridge Cognition Posted: 18/04/2013
• Cambridge Cognition Posted: 12/04/2013
• Cambridge Cognition Posted: 04/03/2013

Browse by sector

All companies

• Aim advisers
• Aim Awards
• Aim investor relations
• Cleantech
• Construction
• Consumer
• Electricals
• Financial
• Food
• Health
• Industrial
• Leisure
• Media
• Mobile
• Property
• QUOTED MICRO
• Resources
• Retail
• Security
• Services
• Technology
• Telecoms
• Training
• Transport

• 2.4mNumber of messages posted on SocialGo networks
  
• $38mCost savings generated by ideas from WalMart staff over a two month period